<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03457441</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A03250-53</org_study_id>
    <nct_id>NCT03457441</nct_id>
  </id_info>
  <brief_title>Evaluation of Near Visual Acuity With ODYSIGHT, a Smartphone Based Medical App in Comparison to a Standardized Method</brief_title>
  <acronym>TIL-001</acronym>
  <official_title>Evaluation of Near Visual Acuity With ODYSIGHT, a Smartphone Based Medical Application in Comparison to a Standardized Method</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tilak Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tilak Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the level of agreement between visual parameters tested using OdySight,
      a mobile application, and standards in office methods.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Near visual acuity assessment with OdySight versus with near visual acuity chart</measure>
    <time_frame>1 day ( During evaluation visit)</time_frame>
    <description>To assess the equivalence between a smartphone based evaluation of near visual acuity with ODYSIGHT (NVA module) and a standardized method (Sloan ETDRS near vision letter chart).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Near visual acuity assessment with OdySight versus with ETDRS chart</measure>
    <time_frame>1 day ( During evaluation visit)</time_frame>
    <description>To assess the relation between the ETDRS visual acuity at a 4-meter distance and near visual acuity evaluated with ODYSIGHT (NVA module)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Contrast sensitivity assessment with OdySight versus with Pelli-Robson</measure>
    <time_frame>1 day ( During evaluation visit)</time_frame>
    <description>To compare the smartphone based evaluation of the contrast sensitivity with ODYSIGHT (contrast sensitivity module) and a standardized method (Pelli-Robson chart)</description>
  </other_outcome>
  <other_outcome>
    <measure>Scotoma/metamorphopsia detection with OdySight versus with standard Amsler grid</measure>
    <time_frame>1 day ( During evaluation visit)</time_frame>
    <description>To compare the smartphone based evaluation of the Amsler Grid with ODYSIGHT (Amsler grid module) and standardized methods (paper Amsler Grid)</description>
  </other_outcome>
  <other_outcome>
    <measure>Global functional disorders assessment with Odysight versus with OCT</measure>
    <time_frame>1 day ( During evaluation visit)</time_frame>
    <description>To compare functional disorder(s) detected or measured by ODYSIGHT application with anatomical data (OCT: Optical coherence tomography)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Near Vision</condition>
  <arm_group>
    <arm_group_label>Near visual acuity +1.0 and +0.7 logMAR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with near visual acuity between +1.0 and +0.7 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Near visual acuity +0.6 and +0.3 logMAR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with near visual acuity between +0.6 and +0.3 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Near visual acuity +0.2 and +0.0 logMAR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with near visual acuity between +0.2 and +0.0 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standards vision tests</intervention_name>
    <description>Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application</description>
    <arm_group_label>Near visual acuity +1.0 and +0.7 logMAR</arm_group_label>
    <arm_group_label>Near visual acuity +0.6 and +0.3 logMAR</arm_group_label>
    <arm_group_label>Near visual acuity +0.2 and +0.0 logMAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OdySight medical application assessment</intervention_name>
    <description>Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application</description>
    <arm_group_label>Near visual acuity +1.0 and +0.7 logMAR</arm_group_label>
    <arm_group_label>Near visual acuity +0.6 and +0.3 logMAR</arm_group_label>
    <arm_group_label>Near visual acuity +0.2 and +0.0 logMAR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Able to correctly distinguish the body laterality (left and right)

          -  Able to recognize alphabet letters and read French

          -  Affiliated to or beneficiary of the French health care system

          -  Signed/written informed consent

          -  Subject presenting a level of visual acuity of one of his eyes that fits to one of the
             pre-set cohort (visual acuity between +1.0 and +0.7 logMAR, between +0.6 and +0.3
             logMAR or between +0.2 and 0.0 logMAR); the two eyes can be included in two different
             cohorts.

        Exclusion Criteria:

          -  Any pathology that is considered by the investigator as capable of affecting the
             quality of the main evaluation criteria.

          -  Pregnant and breastfeeding women.

          -  Subject not considered by the investigator or designee to correctly use OdySight
             modules after the training session
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saddek Mohan-Saïd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edouard Gasser</last_name>
    <phone>+33 (0)7 62 27 18 42</phone>
    <email>egasser@tilakhealthcare.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Brucker, PhD</last_name>
    <phone>+33 (0)7 64 67 29 52</phone>
    <email>jbrucker@tilakhealthcare.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier National d'Ophtahlomogie du Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minh Hà TRAN</last_name>
      <email>mhtran@15-20.fr</email>
    </contact>
    <investigator>
      <last_name>Saddek Mohand-Saïd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

